A review on melatonin action as therapeutic agent in cancer
Soumya Nair, Sandra Suresh, Arya Kaniyassery, Panchami Jaya, Jayanthi Abraham
A review on melatonin action as therapeutic agent in cancer
BACKGROUND: Melatonin is a hormone which is produced from pineal gland in human and is said to have various impacts in human body like controlling sleep wake cycle, regulating the immune and cardiovascular system and regulating the peripheral organ functioning to name a few. Researchers have reported that the melatonin levels correlates with cancer risks.
OBJECTIVE: In this review article, focus has been given to the therapeutic applications and impact of melatonin hormone in human behavior and physiologic activities. Through this article we aim in compiling the scattered information regarding melatonin and its various aspects of importance in human system.
METHODS: We made an analysis of existing hypothesis and studies published on melatonin and circadian rhythm, factors effecting Melatonin secretions in body, sleep disturbances and cancer risks and melatonin therapy in cancer patients.
RESULTS: Melatonin's role as an endogenous synchronizer, growing evidence suggests its anti-oxidative activity as well as its having a role in modulating immune responses. Fluctuating melatonin levels can be boosted by ingesting products containing melatonin. A large portion of the examinations detailed by the researchers clearly conclude that keeping up an impeccable sleep-wake cycle and having a healthy diet is extremely important to keep up the regular melatonin levels and in order to stay fit.
CONCLUSION: Melatonin is considered as a critical hormone that controls and regulates many functions in our body. Melatonin production is emphatically related to the night time duration. Its most absolute biological role is to convey information to the body about day length for a variety of physiologic functions. In addition to melatonin's role as an endogenous synchronizer, growing evidence suggests its anti-oxidative activity as well as its having a role in modulating immune responses. At present, a growing interest is focused on the validity of the anti-tumor mechanisms of melatonin.
Melatonin / circadian rhythm / breast cancer / pineal gland / melatonin therapy / peripheral organ functioning
[8] |
Abbas S A, Khan U A, Helal Uddin A B M (2011). Seasonal changes effects on the serotonin and Melatonin transmission. Can J App Sci, 1(2): 1–9
|
[9] |
Ames B N, Gold L S (1990). Dietary carcinogens, environmental pollution, and cancer: some misconceptions. Med Oncol Tumor Pharmacother, 7(2-3): 69–85
Pubmed
|
[10] |
Anisimov V N, Kvetnoy I M, Chumakova N K, Kvetnaya T V, Molotkov A O, Pogudina N A, Popovich I G, Popuchiev V V, Zabezhinski M A, Bartsch H, Bartsch C (1999). Melatonin and colon carcinogenesis. II. Intestinal melatonin-containing cells and serum melatonin level in rats with 1,2-dimethylhydrazine-induced colon tumors. Exp Toxicol Pathol, 51(1): 47–52
CrossRef
Pubmed
Google scholar
|
[11] |
Anisimov V N, Popovich I G, Shtylik A V, Zabezhinski M A, Ben-Huh H, Gurevich P, Berman V, Tendler Y, Zusman I (2000a). Melatonin and colon carcinogenesis. III. Effect of melatonin on proliferative activity and apoptosis in colon mucosa and colon tumors induced by 1,2-dimethylhydrazine in rats. Exp Toxicol Pathol, 52(1): 71–76
CrossRef
Pubmed
Google scholar
|
[12] |
Anisimov V N, Popovich I G, Zabezhinski M A (1997). Melatonin and colon carcinogenesis: I. Inhibitory effect of melatonin on development of intestinal tumors induced by 1,2-dimethylhydrazine in rats. Carcinogenesis, 18(8): 1549–1553
CrossRef
Pubmed
Google scholar
|
[13] |
Anisimov V N, Zabezhinski M A, Popovich I G, Zaripova E A, Musatov S A, Andre V, Vigreux C, Godard T, Sichel F (2000b). Inhibitory effect of melatonin on 7, 12-dimethylbenz[a]anthracene-induced carcinogenesis of the uterine cervix and vagina in mice and mutagenesis in vitro. Cancer Lett, 156(2): 199–205
CrossRef
Pubmed
Google scholar
|
[14] |
Attenburrow M E, Cowen P J, Sharpley A L (1996). Low dose melatonin improves sleep in healthy middle-aged subjects. Psychopharmacology (Berl), 126(2): 179–181
CrossRef
Pubmed
Google scholar
|
[15] |
Bartsch C, Bartsch H, Fuchs U, Lippert T H, Bellmann O, Gupta D (1989). Stage-dependent depression of melatonin in patients with primary breast cancer. Correlation with prolactin, thyroid stimulating hormone, and steroid receptors. Cancer, 64(2): 426–433
CrossRef
Pubmed
Google scholar
|
[16] |
Bartsch C, Bartsch H, Schmidt A, Ilg S, Bichler K H, Flüchter S H (1992). Melatonin and 6-sulfatoxymelatonin circadian rhythms in serum and urine of primary prostate cancer patients: evidence for reduced pineal activity and relevance of urinary determinations. Clin Chim Acta, 209(3): 153–167
CrossRef
Pubmed
Google scholar
|
[17] |
Benarroch E E (2008). Suprachiasmatic nucleus and melatonin: reciprocal interactions and clinical correlations. Neurology, 71(8): 594–598
CrossRef
Pubmed
Google scholar
|
[18] |
Blask D E (2009). Melatonin, sleep disturbance and cancer risk. Sleep Med Rev, 13(4): 257–264
CrossRef
Pubmed
Google scholar
|
[19] |
Blask D E, Dauchy R T, Sauer L A (2005). Putting cancer to sleep at night: the neuroendocrine/circadian melatonin signal. Endocrine, 27(2): 179–188
CrossRef
Pubmed
Google scholar
|
[20] |
Blask D E, Dauchy R T, Sauer L A, Krause J A (2004). Melatonin uptake and growth prevention in rat hepatoma 7288CTC in response to dietary melatonin: melatonin receptor-mediated inhibition of tumour linoleic acid metabolism to the growth signaling molecule 13-hydroxyoctadecadienoic acid and the potential role of phytomelatonin. Laboratory of Chrono-Neuroendocrine Oncology, Bassett Research Institute, Cooperstown, NY, USA. Carcinogenesi, 25(6): 951–960
CrossRef
Pubmed
Google scholar
|
[21] |
Blask D E, Lemus-Wilson A M, Wilson S T (1992). Breast cancer: a model system for studying the neuroendocrine role of pineal melatonin in oncology. Biochem Soc Trans, 20(2): 309–311
CrossRef
Pubmed
Google scholar
|
[22] |
Blask D E, Sauer L A, Dauchy R T (2002). Melatonin as a chronobiotic/anticancer agent: cellular, biochemical, and molecular mechanisms of action and their implications for circadian-based cancer therapy. Curr Top Med Chem, 2(2): 113–132
CrossRef
Pubmed
Google scholar
|
[23] |
Brzezinski A (1997). Melatonin in humans. N Engl J Med, 336(3): 186–195
CrossRef
Pubmed
Google scholar
|
[24] |
Cardinali D P, Pagano E S, Scacchi Bernasconi P A, Reynoso R, Scacchi P (2013). Melatonin and mitochondrial dysfunction in the central nervous system. Horm Behav, 63(2): 322–330
CrossRef
Pubmed
Google scholar
|
[25] |
Cini G, Coronnello M, Mini E, Neri B (1998). Melatonin’s growth-inhibitory effect on hepatoma AH 130 in the rat. Cancer Lett, 125(1-2): 51–59
CrossRef
Pubmed
Google scholar
|
[26] |
Claustrat B, Brun J, Chazot G (2005). The basic physiology and pathophysiology of melatonin. Sleep Med Rev, 9(1): 11–24
CrossRef
Pubmed
Google scholar
|
[27] |
Cohen M, Lippman M, Chabner B (1978). Role of pineal gland in aetiology and treatment of breast cancer. Lancet, 2(8094): 814–816
CrossRef
Pubmed
Google scholar
|
[28] |
Cos S, Fernández F, Sánchez-Barceló E J (1996). Melatonin inhibits DNA synthesis in MCF-7 human breast cancer cells in vitro. Life Sci, 58(26): 2447–2453
CrossRef
Pubmed
Google scholar
|
[29] |
Cos S, Fernández R, Güézmes A, Sánchez-Barceló E J (1998). Influence of melatonin on invasive and metastatic properties of MCF-7 human breast cancer cells. Cancer Res, 58(19): 4383–4390
Pubmed
|
[30] |
Cos S, González A, Martínez-Campa C, Mediavilla M D, Alonso-González C, Sánchez-Barceló E J (2006). Estrogen-signaling pathway: a link between breast cancer and melatonin oncostatic actions. Cancer Detect Prev, 30(2): 118–128
CrossRef
Pubmed
Google scholar
|
[31] |
Cos S, Mediavilla M D, Fernández R, González-Lamuño D, Sánchez-Barceló E J (2002). Does melatonin induce apoptosis in MCF-7 human breast cancer cells in vitro? J Pineal Res, 32(2): 90–96
CrossRef
Pubmed
Google scholar
|
[32] |
Crespo D, Fernández-Viadero C, Verduga R, Ovejero V, Cos S (1994). Interaction between melatonin and estradiol on morphological and morphometric features of MCF-7 human breast cancer cells. J Pineal Res, 16(4): 215–222
CrossRef
Pubmed
Google scholar
|
[33] |
Dietz B M, Kang Y H, Liu G, Eggler A L, Yao P, Chadwick L R, Pauli G F, Farnsworth N R, Mesecar A D, van Breemen R B, Bolton J L (2005). Xanthohumol isolated from Humulus lupulus Inhibits menadione-induced DNA damage through induction of quinone reductase. Chem Res Toxicol, 18(8): 1296–1305
CrossRef
Pubmed
Google scholar
|
[34] |
Dimitrov S, Lange T, Tieken S, Fehm H L, Born J (2004). Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans. Brain Behav Immun, 18(4): 341–348
CrossRef
Pubmed
Google scholar
|
[35] |
Dubocovich M L, Delagrange P, Krause D N, Sugden D, Cardinali D P, Olcese J (2010). International Union of Basic and Clinical Pharmacology. LXXV. Nomenclature, classification, and pharmacology of G protein-coupled melatonin receptors. Pharmacol Rev, 62(3): 343–380
CrossRef
Pubmed
Google scholar
|
[36] |
Eagles J M (2004). Seasonal affective disorder: a vestigial evolutionary advantage? Med Hypotheses, 63(5): 767–772
CrossRef
Pubmed
Google scholar
|
[37] |
Fonzi S, Solinas G P, Costelli P, Parodi C, Murialdo G, Bo P, Albergati A, Montalbett i L, Savoldi F, Polleri A (1994). Melatonin and cortisol circadian secretion during ethanol withdrawal in chronic alcoholics. Chronobiologia, 21(1-2): 109–112
Pubmed
|
[38] |
Gilad E, Laufer M, Matzkin H, Zisapel N (1999). Melatonin receptors in PC3 human prostate tumor cells. J Pineal Res, 26(4): 211–220
CrossRef
Pubmed
Google scholar
|
[39] |
Gregg D J (2004). Seasonal affective disorder (SAD). Retrieved from http://www.talkaboutsleep.com/sleep-disorders/2004/09/circadian-jacobs-sad.htm
|
[40] |
Guerrero J M and Reiter R J (2002). Melatonin-Immune System Relationships. Bentham Science Publishers. Current Topics in Medicinal Chemistry, 2(2): 167–179(13).
|
[41] |
Hardeland R (2005). Antioxidative protection by melatonin: multiplicity of mechanisms from radical detoxification to radical avoidance. Endocrine, 27(2): 119–130
CrossRef
Pubmed
Google scholar
|
[42] |
Hill S M, Blask D E (1988). Effects of the pineal hormone melatonin on the proliferation and morphological characteristics of human breast cancer cells (MCF-7) in culture. Cancer Res, 48(21): 6121–6126
Pubmed
|
[43] |
Illnerová H, Buresová M, Presl J (1993). Melatonin rhythm in human milk. J Clin Endocrinol Metab, 77(3): 838–841
Pubmed
|
[44] |
Imai K, Matsuyama S, Miyake S, Suga K, Nakachi K (2000). Natural cytotoxic activity of peripheral-blood lymphocytes and cancer incidence: an 11-year follow-up study of a general population. Lancet, 356(9244): 1795–1799
CrossRef
Pubmed
Google scholar
|
[45] |
Jakóbisiak M, Lasek W, Gołab J (2003). Natural mechanisms protecting against cancer. Immunol Lett, 90(2-3): 103–122
CrossRef
Pubmed
Google scholar
|
[46] |
Jung-Hynes B, Huang W, Reiter R J, Ahmad N (2010). Melatonin resynchronizes dysregulated circadian rhythm circuitry in human prostate cancer cells. J Pineal Res, 49(1): 60–68
Pubmed
|
[47] |
Jung-Hynes B, Reiter R J, Ahmad N (2010). Sirtuins, melatonin and circadian rhythms: building a bridge between aging and cancer. J Pineal Res, 48(1): 9–19
CrossRef
Pubmed
Google scholar
|
[48] |
Kanishi Y, Kobayashi Y, Noda S, Ishizuka B, Saito K (2000). Differential growth inhibitory effect of melatonin on two endometrial cancer cell lines. J Pineal Res, 28(4): 227–233
CrossRef
Pubmed
Google scholar
|
[49] |
Karbownik M, Lewinski A, Reiter R J (2001). Anticarcinogenic actions of melatonin which involve antioxidative processes: comparison with other antioxidants. Int J Biochem Cell Biol, 33(8): 735–753
CrossRef
Pubmed
Google scholar
|
[50] |
Karbownik M, Reiter R J (2002). Melatonin protects against oxidative stress caused by d-aminolevulinic acid: implications for cancer reduction. Cancer Invest, 20(2): 276–286
CrossRef
Pubmed
Google scholar
|
[51] |
Klaunig J E, Xu Y, Isenberg J S, Bachowski S, Kolaja K L, Jiang J, Stevenson D E, Walborg E FJr (1998). The role of oxidative stress in chemical carcinogenesis. Environ Health Perspect, 106(Suppl 1): 289–295
CrossRef
Pubmed
Google scholar
|
[52] |
Kriya L D, Arleigh J R, Gianluca T, Wendell W K, Lawrence K D (2007). Seasonal and diurnal melatonin production in exercising sled dogs. Comparative Biochem and Physio- Part A: Molecular & Integrative Physio., (Article in Press)
|
[53] |
Krueger J M, Fang J, Hansen M K, Zhang J, Obál FJr (1998). Humoral regulation of sleep. News Physiol Sci, 13: 189–194
Pubmed
|
[54] |
Lee C O (2006). Complementary and alternative medicines patients are talking about: melatonin. Clin J Oncol Nurs, 10(1): 105–107
CrossRef
Pubmed
Google scholar
|
[55] |
Lee K, Cho M, Miaskowski C, Dodd M (2004). Impaired sleep and rhythms in persons with cancer. Sleep Med Rev, 8(3): 199–212
CrossRef
Pubmed
Google scholar
|
[56] |
Lichtenstein P, Holm N V, Verkasalo P K, Iliadou A, Kaprio J, Koskenvuo M, Pukkala E, Skytthe A, Hemminki K (2000). Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med, 343(2): 78–85
CrossRef
Pubmed
Google scholar
|
[57] |
Lyon R C, McComb J A, Schreurs J, Goldstein D B (1981). A relationship between alcohol intoxication and the disordering of brain membranes by a series of short-chain alcohols. J Pharmacol Exp Ther, 218(3): 669–675
Pubmed
|
[58] |
Maronde E, Stehle J H (2007). The mammalian pineal gland: known facts, unknown facets. Trends Endocrinol Metab, 18(4): 142–149
CrossRef
Pubmed
Google scholar
|
[59] |
Maurizi C P (1990). The therapeutic potential for tryptophan and melatonin: possible roles in depression, sleep, Alzheimer’s disease and abnormal aging. Med Hypotheses, 31(3): 233–242
CrossRef
Pubmed
Google scholar
|
[60] |
Mediavilla M D, Cos S, Sánchez-Barceló E J (1999). Melatonin increases p53 and p21WAF1 expression in MCF-7 human breast cancer cells in vitro. Life Sci, 65(4): 415–420
CrossRef
Pubmed
Google scholar
|
[61] |
Mills E, Wu P, Seely D, Guyatt G (2005). Melatonin in the treatment of cancer: a systematic review of randomized controlled trials and meta-analysis. J Pineal Res, 39(4): 360–366
CrossRef
Pubmed
Google scholar
|
[62] |
Mocchegiani E, Perissin L, Santarelli L, Tibaldi A, Zorzet S, Rapozzi V, Giacconi R, Bulian D, Giraldi T (1999). Melatonin administration in tumor-bearing mice (intact and pinealectomized) in relation to stress, zinc, thymulin and IL-2. Int J Immunopharmacol, 21(1): 27–46
CrossRef
Pubmed
Google scholar
|
[63] |
Molis T M, Spriggs L L, Hill S M (1994). Modulation of estrogen receptor mRNA expression by melatonin in MCF-7 human breast cancer cells. Mol Endocrinol, 8(12): 1681–1690
Pubmed
|
[64] |
Musatov S A, Anisimov V N, André V, Vigreux C, Godard T, Sichel F (1999). Effects of melatonin on N-nitroso-N-methylurea-induced carcinogenesis in rats and mutagenesis in vitro (Ames test and COMET assay). Cancer Lett, 138(1-2): 37–44
CrossRef
Pubmed
Google scholar
|
[65] |
Nosjean O, Nicolas J P, Klupsch F, Delagrange P, Canet E, Boutin J A (2001). Comparative pharmacological studies of melatonin receptors: MT1, MT2 and MT3/QR2. Tissue distribution of MT3/QR2. Biochem Pharmacol, 61(11): 1369–1379
CrossRef
Pubmed
Google scholar
|
[66] |
Pacchierotti C, Iapichino S, Bossini L, Pieraccini F, Castrogiovanni P (2001). Melatonin in psychiatric disorders: a review on the melatonin involvement in psychiatry. Front Neuroendocrinol, 22(1): 18–32
CrossRef
Pubmed
Google scholar
|
[67] |
Pandi-Perumal S R, Trakht I, Srinivasan V, Spence D W, Maestroni G J M, Zisapel N, Cardinali D P (2008). Physiological effects of melatonin: role of melatonin receptors and signal transduction pathways. Prog Neurobiol, 85(3): 335–353
CrossRef
Pubmed
Google scholar
|
[68] |
Panzer A, Lottering M L, Bianchi P, Glencross D K, Stark J H, Seegers J C (1998). Melatonin has no effect on the growth, morphology or cell cycle of human breast cancer (MCF-7), cervical cancer (HeLa), osteosarcoma (MG-63) or lymphoblastoid (TK6) cells. Cancer Lett, 122(1-2): 17–23
CrossRef
Pubmed
Google scholar
|
[69] |
Patel S R, Ayas N T, Malhotra M R, White D P, Schernhammer E S, Speizer F E, Stampfer M J, Hu F B (2004). A prospective study of sleep duration and mortality risk in women. Sleep, 27(3): 440–444
CrossRef
Pubmed
Google scholar
|
[70] |
Petranka J, Baldwin W, Biermann J, Jayadev S, Barrett J C, Murphy E (1999). The oncostatic action of melatonin in an ovarian carcinoma cell line. J Pineal Res, 26(3): 129–136
CrossRef
Pubmed
Google scholar
|
[71] |
Peuhkuri K, Sihvola N, Korpela R (2012). Dietary factors and fluctuating levels of melatonin. Food Nutr Res, 56(1): 17252
CrossRef
Pubmed
Google scholar
|
[72] |
Qi W, Reiter R J, Tan D X, Manchester L C, Calvo J R (2001). Melatonin prevents d-aminolevulinic acid-induced oxidative DNA damage in the presence of Fe2+. Mol Cell Biochem, 218(1-2): 87–92
CrossRef
Pubmed
Google scholar
|
[73] |
Ram P T, Yuan L, Dai J, Kiefer T, Klotz D M, Spriggs L L, Hill S M (2000). Differential responsiveness of MCF-7 human breast cancer cell line stocks to the pineal hormone, melatonin. J Pineal Res, 28(4): 210–218
CrossRef
Pubmed
Google scholar
|
[74] |
Reiter R J (1980). The pineal and its hormones in the control of reproduction in mammals. Endocr Rev, 1(2): 109–131
CrossRef
Pubmed
Google scholar
|
[75] |
Riabykh T P, Nikolaeva T G, Bodrova N B (2000). [Effects of biorhythm regulator melatonin on DNA synthesis in short-term cultures of human malignant tumors]. Vestn Ross Akad Med Nauk, (8): 30–33
Pubmed
|
[76] |
Schernhammer E S, Berrino F, Krogh V, Secreto G, Micheli A, Venturelli E, Sieri S, Sempos C T, Cavalleri A, Schünemann H J, Strano S, Muti P (2008). Urinary 6-sulfatoxymelatonin levels and risk of breast cancer in postmenopausal women. J Natl Cancer Inst, 100(12): 898–905
CrossRef
Pubmed
Google scholar
|
[77] |
Schernhammer E S, Hankinson S E (2003). Light at night: a novel risk factor for cancer in shift workers. Clin Occup Environ Med, 3(2): 263–278
CrossRef
Google scholar
|
[78] |
Shiu S Y, Li L, Xu J N, Pang C S, Wong J T, Pang S F (1999). Melatonin-induced inhibition of proliferation and G1/S cell cycle transition delay of human choriocarcinoma JAr cells: possible involvement of MT2 (MEL1B) receptor. J Pineal Res, 27(3): 183–192
CrossRef
Pubmed
Google scholar
|
[79] |
Spiegel D, Giese-Davis J (2003). Depression and cancer: mechanisms and disease progression. Biol Psychiatry, 54(3): 269–282
CrossRef
Pubmed
Google scholar
|
[80] |
Stevens R G, Rea M.0S (2001). Light in the built-in environment: potential role of circadian disruption in endocrine disruption and breast cancer. CCC, 12: 279–87.
|
[81] |
Sturgeon S R, Luisi N, Balasubramanian R, Reeves K W (2012). Sleep duration and endometrial cancer risk. Cancer Causes Control, 23(4): 547–553
CrossRef
Pubmed
Google scholar
|
[82] |
Sze S F, Ng T B, Liu W K (1993). Antiproliferative effect of pineal indoles on cultured tumor cell lines. J Pineal Res, 14(1): 27–33
CrossRef
Pubmed
Google scholar
|
[83] |
Tamarkin L, Cohen M, Roselle D, Reichert C, Lippman M, Chabner B (1981). Melatonin inhibition and pinealectomy enhancement of 7,12-dimethylbenz(a)anthracene-induced mammary tumors in the rat. Cancer Res, 41(11 Pt 1): 4432–4436
Pubmed
|
[84] |
Tan D X, Manchester L C, Hardeland R, Lopez-Burillo S, Mayo J C, Sainz R M, Reiter R J (2003). Melatonin: a hormone, a tissue factor, an autocoid, a paracoid, and an antioxidant vitamin. J Pineal Res, 34(1): 75–78
CrossRef
Pubmed
Google scholar
|
[85] |
Tan D X, Manchester L C, Terron M P, Flores L J, Reiter R J (2007). One molecule, many derivatives: a never-ending interaction of melatonin with reactive oxygen and nitrogen species? J Pineal Res, 42(1): 28–42
CrossRef
Pubmed
Google scholar
|
[86] |
Touitou Y, Fèvre M, Lagoguey M, Carayon A, Bogdan A, Reinberg A, Beck H, Cesselin F, Touitou C (1981). Age- and mental health-related circadian rhythms of plasma levels of melatonin, prolactin, luteinizing hormone and follicle-stimulating hormone in man. J Endocrinol, 91(3): 467–475
CrossRef
Pubmed
Google scholar
|
[87] |
Travis R C, Allen D S, Fentiman I S, Key T J (2004). Melatonin and breast cancer: a prospective study. J Natl Cancer Inst, 96(6): 475–482
CrossRef
Pubmed
Google scholar
|
[88] |
Üstundag A, Duydu Y (2007). The influence of melatonin and N-acetylcysteine in d-aminolevulinic acid and lead induced genotoxicity in lymphocytes in vitro. Biol Trace Elem Res, 117(1-3): 53–64
CrossRef
Pubmed
Google scholar
|
[89] |
Valtonen M, Kangas A P, Voutilainen M, Eriksson L (2003). Diurnal rhythm of melatonin in young calves and intake of melatonin in milk. Anim Sci, 77(1): 149–154
|
[90] |
van der Goot A T, Nollen E A (2013). Tryptophan metabolism: entering the field of aging and age-related pathologies. Trends Mol Med, 19(6): 336–344
CrossRef
Pubmed
Google scholar
|
[91] |
Vijayalaxmi , Thomas C R J, Reiter R J, Herman T S(2002). Melatonin: from basic research to cancer treatment clinics. J Clin Oncol, 20: 2575–2601.
|
[92] |
Waldhauser F, Waldhauser M (1988). Melatonin and ageing. A Miles, D.R.S Philbrick, C Thompson (Eds.), Melatonin—Clinical Perspectives, Oxford University Press, Oxford. pp. 174–189
|
[93] |
Walecka-Kapica E, Klupińska G, Chojnacki J, Tomaszewska-Warda K, Błońska A, Chojnacki C (2014). The effect of melatonin supplementation on the quality of sleep and weight status in postmenopausal women. Przegl Menopauz, 13(6): 334–338
CrossRef
Pubmed
Google scholar
|
[94] |
Wu A H, Wang R, Koh W P, Stanczyk F Z, Lee H P, Yu M C (2008). Sleep duration, melatonin and breast cancer among Chinese women in Singapore. Carcinogenesis, 29(6): 1244–1248
CrossRef
Pubmed
Google scholar
|
[95] |
Wurtman R J, Axelrod J, Barchas J D (1964). Age and Enzyme Activity in the Human Pineal. J Clin Endocrinol Metab, 24(3): 299–301
CrossRef
Pubmed
Google scholar
|
[96] |
Ying S W, Niles L P, Crocker C (1993). Human malignant melanoma cells express high-affinity receptors for melatonin: antiproliferative effects of melatonin and 6-chloromelatonin. Eur J Pharmacol, 246(2): 89–96
CrossRef
Pubmed
Google scholar
|
[97] |
Yuan L, Collins A R, Dai J, Dubocovich M L, Hill S M (2002). MT(1) melatonin receptor overexpression enhances the growth suppressive effect of melatonin in human breast cancer cells. Mol Cell Endocrinol, 192(1-2): 147–156
CrossRef
Pubmed
Google scholar
|
[98] |
Zawilska J B, Lorenc A, Berezińska M, Vivien-Roels B, Pévet P, Skene D J (2006). Diurnal and circadian rhythms in melatonin synthesis in the turkey pineal gland and retina. Gen Comp Endocrinol, 145(2): 162–168
CrossRef
Pubmed
Google scholar
|
[99] |
Zee P C, Attarian H, Videnovic A (2013). Circadian rhythm abnormalities. Continuum (Minneap Minn), 19(1 Sleep Disorders): 132–147
Pubmed
|
/
〈 | 〉 |